Spectaire (SPEC) Competitors

Telesis Bio (NASDAQ:TBIO) and Spectaire (NASDAQ:SPEC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Does the media favor TBIO or SPEC?

In the previous week, Telesis Bio's average media sentiment score of 0.00 equaled Spectaire'saverage media sentiment score.

Company	Overall Sentiment
Telesis Bio	Neutral
Spectaire	Neutral

Does the MarketBeat Community believe in TBIO or SPEC?

Telesis Bio received 9 more outperform votes than Spectaire when rated by MarketBeat users. Likewise, 52.94% of users gave Telesis Bio an outperform vote while only 0.00% of users gave Spectaire an outperform vote.

Company	Underperform	Outperform
Telesis Bio	Outperform Votes 9 52.94%	Underperform Votes 8 47.06%
Spectaire	Outperform Votes No Votes	Underperform Votes 1 100.00%

Which has preferable earnings & valuation, TBIO or SPEC?

Spectaire has lower revenue, but higher earnings than Telesis Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telesis Bio	$225.09M	0.00	-$47.72M	-$28.20	-0.01
Spectaire	N/A	N/A	$8.95M	N/A	N/A

Which has more risk and volatility, TBIO or SPEC?

Telesis Bio has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Spectaire has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Do institutionals & insiders believe in TBIO or SPEC?

37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 26.6% of Spectaire shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is TBIO or SPEC more profitable?

Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Telesis Bio's return on equity of 0.00% beat Spectaire's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telesis Bio	-336.59%	N/A	-61.89%
Spectaire	N/A	-81.22%	304.57%

Summary

Telesis Bio beats Spectaire on 6 of the 10 factors compared between the two stocks.